Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the dissolution of its wholly owned subsidiary, Curatio Inc., Philippines, with effect from July 10, 2026. The company has received communication of the dissolution on July 17, 2026, and has provided details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about General Updates, specifically that Crisil ESG Ratings & Analytics Limited has independently assigned the rating of 'Crisil ESG 66' and the Core ESG rating of 'Crisil Core ESG 74'.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has scheduled a teleconference with investors and analysts on July 30, 2026, to discuss the financial performance for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited is implementing a voluntary recall of select batches of Semalix injection disposable pens as a precautionary measure due to a product recall notification from its manufacturer Dr. Reddy's Laboratories Ltd.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about a special window for transfer and dematerialization requests of physical shares, as published in the Financial Express newspaper.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, following the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited, which has become effective on 8th July, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the effectiveness of the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited, as approved by the Hon'ble National Company Law Tribunal, Ahmedabad Bench.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of OT is 17-Jul-2026, in relation to the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the receipt of a certified true copy of the Order passed by the National Company Law Tribunal, Ahmedabad Bench, regarding the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the sanction of the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders by the Hon'ble National Company Law Tribunal.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited successfully held its 53rd Annual General Meeting on June 23, 2026, and announced that all resolutions were duly approved by shareholders. Key resolutions passed included the adoption of standalone and consolidated financial statements for FY2026, confirmation of interim dividend and declaration of final dividend, re-appointment of Director Samir Mehta, and ratification of cost auditor remuneration. Significantly, shareholders also approved a special resolution for the issuance of equity shares including convertible bonds/debentures, enabling future capital raising activities.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited's 53rd Annual General Meeting (AGM) on June 23, 2026, approved standalone and consolidated financial statements for FY26. Shareholders confirmed an interim dividend of ₹29.00 and declared a final dividend of ₹9.00 per equity share for FY26. Key resolutions also included the re-appointment of Director Samir Mehta, ratification of cost auditor remuneration, and the approval for the issuance of equity shares including convertible bonds/debentures, signaling potential future capital raising.